Study details
Enrolling now
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Brigham and Women's Hospital
NCT IDNCT05030545ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 4.2 years
Ages
18–85
Locations
1 site in MA
What this study is about
This trial is testing a treatment to see if it improves heart function in people with primary aldosteronism. This condition causes the body to make too much aldosterone, which can lead to high blood pressure and increase the risk of heart disease. The goal is to determine if blocking aldosterone reduces cardiovascular problems.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Eplerenone
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
eplerenone
Drug routes
oral (Oral Tablet)
Body systems
Cardiology / Heart